



A Simple-to-Perform *ifn-γ* mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation

OPEN ACCESS

Edited by:

Raffaella Greco,
San Raffaele Hospital (IRCCS), Italy

Reviewed by:

Vicki Traina-Dorge,
Tulane University, United States
Varun Mehra,
King's College Hospital NHS
Foundation Trust, United Kingdom

*Correspondence:

Florence Ader
florence.ader@chu-lyon.fr

†These authors have contributed
equally to this work and share
first authorship

Specialty section:

This article was submitted to
Alloimmunity and Transplantation,
a section of the journal
Frontiers in Immunology

Received: 13 April 2022

Accepted: 20 June 2022

Published: 27 July 2022

Citation:

Boccard M, Conrad A, Mouton W,
Valour F, Roure-Sobas C, Frobert E,
Rohmer B, Alcazer V,
Labussière-Wallet H, Ghesquières H,
Venet F, Brengel-Pesce K,
Trouillet-Assant S and Ader F (2022)
A Simple-to-Perform *ifn-γ* mRNA Gene
Expression Assay on Whole Blood
Accurately Appraises Varicella Zoster
Virus-Specific Cell-Mediated Immunity
After Allogeneic Hematopoietic
Stem Cell Transplantation.
Front. Immunol. 13:919806.
doi: 10.3389/fimmu.2022.919806

Mathilde Boccard^{1,2†}, Anne Conrad^{1,2†}, William Mouton^{1,3†}, Florent Valour^{1,2},
Chantal Roure-Sobas⁴, Emilie Frobert^{1,4}, Barbara Rohmer⁵, Vincent Alcazer^{1,6},
Hélène Labussière-Wallet⁶, Hervé Ghesquières^{1,6}, Fabienne Venet^{1,3,7,8},
Karen Brengel-Pesce³, Sophie Trouillet-Assant^{1,3} and Florence Ader^{1,2*}

¹ Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, Lyon, France, ² Département des Maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ³ Laboratoire de Recherche Commun (LCR), Hospices Civils de Lyon/BioMérieux, Pierre-Bénite, France, ⁴ Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁵ Service d'Hépatologie Gastro-Entérologie et Nutrition Pédiatriques, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France, ⁶ Département d'Hématologie clinique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France, ⁷ Laboratoire d'Immunologie, Hospices Civils de Lyon, Lyon, France, ⁸ EA7426 UCBL1-HCL-bioMérieux Pathophysiology of Injury-induced Immunosuppression, Lyon, France

Herpes zoster, which is due to the reactivation of Varicella zoster virus (VZV), is a leading cause of morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While cell-mediated immunity (CMI) is critical to inhibiting VZV reactivation, CMI is not routinely assessed due to a lack of reliable tests. In this study, we aimed to evaluate VZV-specific CMI among allo-HSCT recipients (n = 60) and healthy individuals (HI, n = 17) through a panel of three immune functional assays after *ex vivo* stimulation by VZV antigen: quantification of (i) IFN- γ release in the supernatants, (ii) T-cell proliferation after a 7-day stimulation of peripheral blood mononuclear cells (PBMC), and (iii) measurement of the *ifn-γ* mRNA gene expression level after 24 h of stimulation of a whole-blood sample. VZV responsiveness was defined according to IFN- γ release from VZV-stimulated PBMC. Upon VZV stimulation, we found that allo-HSCT recipients at a median time of 6 [5-8] months post-transplant had lower IFN- γ release (median [IQR], 0.34 [0.12–8.56] vs. 409.5 [143.9–910.2] pg/ml, $P < .0001$) and fewer proliferating T cells (0.05 [0.01–0.57] % vs. 8.74 [3.12–15.05] %, $P < .0001$) than HI. A subset of allo-HSCT recipients (VZV-responders, n = 15/57, 26%) distinguished themselves from VZV-non-responders (n = 42/57, 74%; missing data, n = 3) by higher IFN- γ release (80.45 [54.3–312.8] vs. 0.22 [0.12–0.42] pg/ml, $P < .0001$) and T-cell proliferation (2.22 [1.18–7.56] % vs. 0.002

[0.001–0.11] %, $P < .0001$), suggesting recovery of VZV-specific CMI. Interestingly, VZV responders had a significant fold increase in *ifn- γ* gene expression, whereas *ifn- γ* mRNA was not detected in whole blood of VZV-non-responders ($P < .0001$). This study is the first to suggest that measurement of *ifn- γ* gene expression in 24-h-stimulated whole blood could be an accurate test of VZV-specific CMI. The routine use of this immune functional assay to guide antiviral prophylaxis at an individual level remains to be evaluated.

Keywords: varicella zoster virus, hematopoietic stem cell transplantation, cell-mediated immunity, immune functional assays, interferon gamma, antiviral prophylaxis

INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are at increased risk of reactivation of latent varicella zoster virus (VZV) infection, with up to half of patients experiencing herpes zoster (HZ) during the first 5 years post-transplant (1–4). In addition, HZ may be more severe after allo-HSCT and exposes recipients to complications ranging from post-herpetic neuralgia to threatening disseminated disease (4–7). Although there is no immunological correlate of protection, T-cell response is thought to be the main driver of immune-mediated control of latent VZV infection (8–12). Indeed, the risk of HZ is highest during the first 24 months post-transplant, a period which corresponds to the phase of reconstitution of adaptive immunity after allo-HSCT (1–4, 13–15). Vaccination might be an interesting option to enhance VZV immunity. However, the recombinant subunit zoster vaccine (RZV) is not available in many countries while the live-attenuated VZV vaccines are contraindicated during the first 24 months post-transplant. Data regarding immunogenicity and safety of these vaccines are scarce in this setting. Pending recovery of VZV-specific immunity, complementary prophylactic strategies are thus essential to preventing VZV disease.

Currently, prevention of VZV disease in seropositive allo-HSCT recipients relies on antiviral prophylaxis with (val)acyclovir or famciclovir recommended for at least 12 months post-transplant or longer in case of protracted immune recovery (6, 16). Duration of antiviral prophylaxis may be different from a recipient to another, raising the issue of the optimal timing of discontinuation (16, 17). An informative test of VZV-specific cell-mediated immunity status could therefore help to manage VZV prophylaxis at a personalized level.

VZV-specific cell-mediated immunity can be assessed by immune functional assays (IFA) which evaluate cellular immune responses to *in vitro* stimulation by VZV antigens. These assays can be performed on peripheral blood mononuclear cells (PBMC) or whole-blood samples, and different readouts of VZV-specific cell-mediated immunity can be used, such as evaluation of lymphocyte proliferative response or quantification of interferon (IFN)- γ secretion (IFN- γ release assay, IGRA) (18–23). Nevertheless, assays on PBMC are cumbersome and time- and resource-consuming, so that they are not routinely performed. A fast, reproducible IFA monitoring VZV-specific immunity out of a small volume of whole-blood sample is of major interest to

discriminate recipients having VZV-specific efficient immune response. We hypothesized that an upstream measurement of *ifn- γ* gene expression in 24-h-stimulated whole blood might correlate with VZV-specific cell-mediated immune status, as determined by standard IFA performed on PBMC. In this proof-of-concept, cross-sectional study, we determined the VZV-specific cell-mediated immune status of a cohort of adult allo-HSCT recipients at approximately 6 months post-transplant using three methods: an innovative *ifn- γ* mRNA gene expression assay from a small whole-blood sample, an automatized enzyme-linked immunosorbent IGRA, and an *ex vivo* lymphocyte proliferation assay, both performed on participant PBMC.

MATERIALS AND METHODS

Study Population

Consecutive, adult allo-HSCT recipients transplanted at the hematology department of the Lyon University Hospital (France) and participating in the prospective, single-center “VaccHemInf” cohort study between May 2018 and August 2020 were enrolled. The VaccHemInf cohort study aims at studying vaccine response and immune reconstitution in HSCT recipients, as described elsewhere (24). Briefly, at inclusion, the demographic, hematological, and transplant-related characteristics of allo-HSCT recipients were collected. Immune reconstitution was assessed at a quantitative level (immunophenotyping of lymphocyte subsets, dosing of immunoglobulins) and at a functional level by IFA for an arbitrarily chosen subset of patients (approximately one patient in two). At our center, stem cell grafts are T-cell replete but recipients might receive antithymocyte globulin (ATG), depending on HSCT protocols. VZV-related clinical manifestations were retrospectively retrieved through medical charts. According to local procedures, antiviral prophylaxis by oral valacyclovir 500 mg bid was initiated at allo-HSCT and continued for at least 12 months. The study has been approved by a regional review board (*Comité de Protection des Personnes Sud-Est V*, Grenoble, France, number 69HCL17_0769) and is registered in ClinicalTrials.gov (NCT03659773).

Concomitantly, blood samples from healthy individuals (HI), recruited among adult donors to the Lyon (France) blood bank (*Etablissement Français du Sang*, EFS), were obtained to serve as controls. According to the EFS-standardized procedures for blood donation and to provisions of the articles R.1243–49 and following

ones of the French public health code, a written non-opposition to the use of donated blood for research purposes was obtained from HI. The blood donors' personal data were anonymized before transfer to the research laboratory. Regulatory authorizations for the handling and conservation of these samples were obtained from the regional review board (*Comité de Protection des Personnes Sud-Est II*) and the French ministry of research (*Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation*, DC-2008–64). Blood samples from children (VZV-naïve controls) were provided as part of a study approved by the regional review board (*Comité de Protection des Personnes Sud-Est III*, 2013-011B), French Data Protection Authority (CNIL, DR-2013-354), and French Advisory Committee on Healthcare Research Data Processing (CCTIRS, 2013.223). Parents' written consent was obtained for each participant.

Quantification of VZV Antibodies

VZV-specific immunoglobulin (Ig)G was measured in sera by a chemiluminescence immunoassay (VZV IGG, LIAISON® XL; DiaSorin, Saluggia, Italy) according to the manufacturers' instructions. An IgG antibody titer ≥ 150 mIU/ml was considered positive (25).

IFN- γ Release Assay and T-Cell Proliferation Measured on VZV-Stimulated Peripheral Blood Mononuclear Cells

As previously described, fresh PBMC were purified from a heparin-coated blood tube (24). Fresh PBMC were plated onto a 96-well plate at 1×10^5 cells per well and incubated at 37°C and 5% of CO₂ overnight. PBMC were then stimulated with either VZV grade 2 antigen, a gamma-irradiated antigen preparation corresponding to the supernatants of a VZV-infected cell line (MRC-5 cells; Microbix Biosystems, Mississauga, Ontario, Canada), or MRC-5 control antigen (supernatants from uninfected MRC-5 cells, CTRL) at 20 μ g/l, or medium alone (non-stimulated control, NUL) for 7 days. A 3-day stimulation with phytohemagglutinin (PHA; Remel, Oxoid, Thermo Fisher Scientific, Waltham, MA, USA) at 4 μ g/l served as mitogen control and medium alone (NUL) as its related negative control condition. Concentrations of stimulants, as well as length of incubation, had been determined by preliminary assays (data not shown).

At each time point, IFN- γ was measured in PBMC supernatants using the ELLA nanofluidic system (Bio-Techne, Minneapolis, MI, USA) according to the manufacturers' instructions. All values below the lowest limit of quantification (LLOQ = 0.17 pg/ml) provided by the manufacturer were reduced to a value equal to $LLOQ/\sqrt{2}$ (= 0.12 pg/ml). Patients were classified into "VZV-responders" and "VZV-non-responders" according to the concentration of IFN- γ in supernatants from VZV-stimulated PBMC, with a positivity threshold arbitrarily fixed at twice (4.83 pg/ml) the highest secretion obtained in the control condition (2.415 pg/ml).

Pellets collected from paired wells were analyzed for T-cell proliferation using the Click-It™ EdU AF488 flow kit (C10420; Life Technologies, Carlsbad, CA, USA) to measure incorporation of 5-ethynyl-2'-deoxyuridine (EdU) according to the previously

published protocol (26). Briefly, the percentage of EdU⁺ proliferating cells (among CD3⁺ cells) was obtained by flow cytometry analyses performed on a Navios flow cytometer (Beckman Coulter, Brea, CA, USA). For each experiment, a minimum of 2.5×10^3 CD3⁺ cells were recorded. Data were analyzed using Kaluza software (version 1.2, Beckman Coulter). Values equal to "zero" proliferation were set to 0.01% to be plottable on a logarithmic scale.

ifn- γ mRNA Gene Expression Assay on VZV-Stimulated Whole Blood

Heparinized whole blood (100 μ l) was distributed into a 96-well plate. VZV antigen at 20 μ g/l (VZV), medium alone (non-stimulated control, NUL), or supernatants from uninfected MRC-5 cells (negative control, CTRL) were added to a single well and incubated for 24 h at 37°C and 5% of CO₂. Total RNA was extracted using the RNeasy Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Briefly, the cells were harvested and lysed in RLT buffer (lysis buffer) supplemented with β -mercaptoethanol and stored at -80°C until further processing. RNA quantity and quality were determined using NanoDrop (Thermo Fisher Scientific, MA, USA). For mRNA detection, RNA was retro-transcribed using SuperScript VILO cDNA Synthesis kit (Thermo Fisher) followed by qPCR performed using commercial TaqMan probes for *ifn- γ* (Invitrogen, Carlsbad, CA, USA) and normalized using the mean of *PP1B* and *DECR1* housekeeping genes on CFX Connect Real-Time (RT)-PCR Detection System (Bio-Rad, Hercules, CA, USA). The relative differential expression of the *ifn- γ* gene was expressed as a fold change using the 2- $\Delta\Delta$ Ct method (27). The first Δ CT is the difference in threshold cycle between the *ifn- γ* gene and the geometric mean of housekeeping in all conditions (VZV, CTRL, or NUL). $\Delta\Delta$ CT is the difference of *ifn- γ* gene Δ CT obtained in stimulated conditions (VZV or CTRL) compared to the unstimulated control condition (NUL).

Post-Transplant T-Cell Immunophenotyping

A large panel of T-cell membrane markers was measured by flow cytometry (Beckman Coulter, Villepinte, France) on whole blood. Naïve (CD45RA⁺CCR7⁺) CD4⁺ and CD8⁺ T-cells, central memory (CD45RA⁺CCR7⁺) CD4⁺ and CD8⁺ T-cells, effector memory (CD45RA⁺CCR7⁻) CD4⁺ and CD8⁺ T-cells, and differentiated memory (CD45RA⁺CCR7⁻) CD4⁺ and CD8⁺ T-cells were counted (cells/ μ L), in addition to routine absolute CD4⁺ and CD8⁺ T lymphocyte counts.

Statistical Analysis

Qualitative variables were expressed as counts (percentages), and quantitative continuous data were expressed as mean and range or as median and interquartile range [IQR]. Quantitative non-gaussian data were compared using the Kruskal–Wallis test or the Mann–Whitney test, where appropriate. Qualitative data were compared between groups using Fisher's exact test. The association between quantitative data was quantified by a non-parametric Spearman rank-correlation coefficient (95%

confidence interval [CI]). Two-sided tests were performed with statistical significance defined by $P < .05$. Statistical analyses were conducted using GraphPad Prism[®] software (version 8.3; GraphPad software, La Jolla, CA, USA) and R (version 3.4.4; R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Participant Characteristics

HI ($n = 17$) and allo-HSCT recipients ($n = 60$) were included. HI and allo-HSCT recipients did not significantly differ in terms of

age (median [IQR], 42 [33–51] vs. 44.5 [34–60] years, $P = .39$) and sex (sex ratio, 1.1 vs. 1.3, $P = .79$). Allo-HSCT recipients were enrolled at a median [IQR] time of 6 [5–8] months post-transplant. All HI were VZV-seropositive, 98% ($n = 58/59$; missing data, $n = 1$), and 75% ($n = 45/60$) of allo-HSCT recipients had positive VZV IgG titers prior to transplantation and at enrollment, respectively. Nineteen (32%) allo-HSCT recipients were on immunosuppressive therapy, and 41 (68%) had received intravenous Ig infusions at a median [IQR] time of 4 [3–6] months before inclusion (**Table 1**). VZV IgG titers at inclusion were not higher among patients having received intravenous Ig infusions ($P = .16$). Pediatric controls ($n = 2$) were VZV-naïve.

TABLE 1 | Baseline characteristics of allogeneic hematopoietic stem cell transplantation recipients.

		n = 60
Demographics		
	Age (years), median [IQR]	44.5 [34–60]
	Male, n (%)	34 (57)
Hematological and transplant-related characteristics, n (%)		
<i>Underlying hematological disease*</i>		
	Acute myeloid leukemia and related neoplasms	31 (52)
	Myelodysplastic syndromes	8 (13)
	Myeloproliferative neoplasms	1 (2)
	B-lymphoblastic leukemia/lymphoma	11 (18)
	T-lymphoblastic leukemia/lymphoma	2 (3)
	Mature neoplasms: T, NK, or B cells	3 (5)
	Hodgkin lymphoma	1 (2)
	Others	3 (5)
<i>Donor type</i>		
	Matched sibling donor	18 (30)
	Haploidentical related donor	12 (20)
	Unrelated donor	30 (50)
	Fully matched	23 (38)
	HLA mismatched	7 (12)
<i>Stem cell source</i>		
	Peripheral blood stem cells	48 (80)
	Bone marrow	11 (18)
	Cord blood	1 (2)
<i>Conditioning regimen</i>		
	MAC	22 (37)
	RIC	38 (63)
	TBI	18 (30)
<i>GVHD prophylaxis</i>		
	ATG	34 (57)
	Calcineurin inhibitors	59 (98)
	Mycophenolate mofetil	33 (55)
	Methotrexate	14 (23)
	Post-transplant cyclophosphamide	23 (38)
<i>Recipient VZV status prior to transplantation[†]</i>		
	Positive	58 (98)
	Negative	1 (2)
Post-transplant VZV IgG titers at inclusion (mIU/mL), median [IQR]		418.5 (151.2–1092)
Post-transplant complications, n (%)		
	Acute GvHD	42 (70)
	Grade I/II/III	28/12/2
	Chronic GvHD	8 (13)
	Limited/extensive	5/3
Time from transplantation (months), median [IQR]		6 [5–8]

(Continued)

TABLE 1 | Continued

	n = 60
Immunophenotyping of lymphocyte subsets (cells/μL), mean (range)	
Lymphocytes (NV, 1,000–2,800/ μ L)	1,601 (410–4,910)
CD3 ⁺ T-lymphocytes (NV, 521–1,772/ μ L)	887 (145–3,406)
CD3 ⁺ CD4 ⁺ T-lymphocytes (NV, 336–1,126/ μ L)	270 (38–876)
Naïve CD4 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 121–456/ μ L)	30 (0–390)
CM CD4 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 92–341/ μ L)	61 (1–211)
EM CD4 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 59–321/ μ L)	157 (4–704)
DM CD4 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 11–102/ μ L)	22 (0–226)
CD3 ⁺ CD8 ⁺ T-lymphocytes (NV, 125–780/ μ L)	580 (50–2,779)
Naïve CD8 ⁺ (CD45 ⁺ CCR7 ⁺) (NV, 86–257/ μ L)	39 (0–241)
CM CD8 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 19–93/ μ L)	18 (0–127)
EM CD8 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 15–162/ μ L)	252 (0–1,517)
DM CD8 ⁺ (CD45RA ⁺ CCR7 ⁺) (NV, 39–212/ μ L)	276 (0–1,500)
CD4 ⁺ /CD8 ⁺ ratio (NV, 0.9–6)	0.97 (0.12–9.07)
CD20 ⁺ B-lymphocytes (NV, 64–593/ μ L)	282 (14–1,439)
NK cells (NV, 70–523/ μ L)	235 (30–2,023)
Immunoglobulin G titers (NV, 7–16 g/l)	8.6 (2.0–20.3)
Post-transplant immunomodulatory therapy, n (%)	
IS therapy at inclusion [†]	19 (32)
IVIg infusion(s)	41 (68)
Time since last IVIg infusion (months), median [IQR]	4 [3–6]
DLI	8 (13)

*Based on 2016 revisions of the World Health Organization classification of myeloid and lymphoid neoplasms (28, 29). [†]Missing value, n = 1. [‡]Immunosuppressive therapies included cyclosporine (n = 9), tacrolimus (n = 4), corticosteroids (n = 8), ruxolitinib (n = 3). Abbreviations: ATG, antithymocyte globulin; CM, central memory; DM, differentiated memory; DLI, donor lymphocyte infusion; EM, effector memory; GvHD, graft-versus-host disease; HLA, human leukocyte antigen; IQR, interquartile range; IS, immunosuppressive; Ig, immunoglobulin; IVIG, intravenous immunoglobulins; MAC, myeloablative conditioning; NK, natural killer; NV, normal values; RIC, reduced intensity conditioning; TBI, total body irradiation; VZV, varicella zoster virus.

Cell-Mediated Immunity Upon Phytohemagglutinin Stimulation

First, to verify that HI and allo-HSCT recipients were able to mount a detectable immune response upon mitogen stimulation, IFN- γ in supernatants and proliferation of PHA-stimulated PBMC were determined. HI and allo-HSCT recipients developed a significantly higher IFN- γ release and percentage of EdU⁺ proliferating cells (among CD3⁺ cells) ($P < .0001$ for both) compared to control conditions, indicating that these tests were appropriate to assess lymphocyte functionality in the study population. However, IFN- γ release (median [IQR], 5863 [1,335–16,602] vs. 74,884 [44,574–89,385] pg/ml, $P = .004$) and proliferation capacity of T-cells (median [IQR], 23.8 [14.6–33.7] % vs. 39.9 [34–48.1] %, $P = .02$) were significantly lower in allo-HSCT recipients than in HI (**Supplementary Figure 1**). Among pediatric controls, IFN- γ release and T-cell proliferation (EdU⁺ CD3⁺ cells) upon PHA stimulation were 52.6–210.3 pg/ml and 38.5%–45.4%, respectively.

VZV-Specific Cell-Mediated Immunity

A 7-day stimulation of PBMC with VZV antigen resulted in a significantly lower IFN- γ release in the supernatant (median [IQR], 0.34 [0.12–8.56] vs. 409.5 [143.9–910.2] pg/ml, $P < .0001$) and a significantly lower percentage of EdU⁺ proliferating cells (among CD3⁺ cells) (0.05 [0.01–0.57] % vs. 8.74 [3.12–15.05] %, $P < .0001$) among allo-HSCT recipients as compared to HI (**Figures 1A, B**). Both were highly correlated (Spearman's correlation coefficient 0.87; 95% CI [0.79–0.92]; **Figure 1C**). Conversely, VZV-specific T-cell proliferation was not correlated with unspecific PHA-induced T-cell proliferation

(Spearman's correlation coefficient, 0.07 [95% CI, -0.2–0.34]). Of note, VZV-naïve controls did not mount any proliferative response (no EdU⁺ proliferating CD3⁺ cells: 0%–0%) and had IFN- γ release below LLOQ (0.104–0.131 pg/ml).

Results indicated that allo-HSCT recipients had an impaired VZV-specific T-cell function based on lower proliferation and IFN- γ release post-stimulation. When focusing on allo-HSCT recipients' results, two subsets were observed and classified as VZV responders (n = 15/57, 26%) or non-responders (n = 42/57, 74%; missing data, n = 3) based on IFN- γ secretion level above the positivity threshold (**Table 2**). Among the VZV-responder group, a significantly higher IFN- γ release was observed, as compared to the VZV-non-responder group (median [IQR], 80.45 [54.3–312.8] vs. 0.22 [0.12–0.42] pg/ml, $P < .0001$). The IFN- γ release among the VZV-responder group was lower than among HI (median [IQR], 409.5 [143.9–910.2] pg/ml), but the difference did not reach statistical significance ($P = .64$). Of note, similar observations were made for the VZV-specific proliferative response, with a significant higher proliferation capacity in the VZV-responder group, as compared to the VZV-non-responder group (median [IQR], 2.22 [1.18–7.56] % vs. 0.002 [0.001–0.11] %, $P < .0001$). Proliferative response among the VZV-responder group was lower than in HI without reaching statistical significance (median [IQR], 8.74 [3.12–15.05] %, $P = .76$).

Interestingly, 13/15 (87%) of VZV responders had a positive VZV-specific humoral response, as depicted by higher IgG titers (median [IQR], 1382 [494.4–1577] mIU/ml), as compared to the VZV-non-responder group, where 29/42 (69%) had a positive titer (median [IQR], 383.1 [141.1–664.2] mIU/ml, $P = .005$).




FIGURE 1 | VZV-specific cell-mediated immunity according to immunoassays on peripheral blood mononuclear cells. Peripheral blood mononuclear cells isolated (1×10^5 cells) from healthy individuals (HI, $n = 17$) and allogeneic hematopoietic stem cell transplant recipients (allo-HSCT, $n = 57$) were stimulated by VZV antigen (inactivated supernatants from VZV-infected MRC-5 cells, $20 \mu\text{g/ml}$) or supernatants from VZV-uninfected MRC-5 cells (control condition) and incubated for 7 days in duplicate. **(A)** IFN- γ release (pg/ml) in the supernatants was quantified using the ELLA nanofluidic system. Bars represent median values, black dotted line represents the lower limit of quantification (LLOQ = 0.17 pg/ml), and red dotted line represents the arbitrarily defined threshold of positivity of the assay, i.e., 4.83 pg/ml , corresponding to twice the maximum value observed in the control condition. All values below LLOQ have been set at 0.12 pg/ml corresponding to $\text{LLOQ}/\sqrt{2}$. **(B)** In respective wells, T-cell proliferation is expressed as the percentage of EdU^+ proliferating cells (among CD3^+ cells) measured by flow cytometry after EdU^+ incorporation and completion of the Click-it[®]. Groups were compared using Kruskal–Wallis test; **** $P < .0001$, NS: not significant. Red triangles represent recipients defined as VZV-responders, i.e., having recovered a VZV-specific cellular-mediated immunity according to the IFN- γ release assay. Clear triangles represent recipients who developed herpes zoster-related manifestations. **(C)** Correlation analysis between T-cell proliferation and IFN- γ release results obtained from the same well was performed using Spearman rank-correlation test; the P-values and the correlation coefficient are indicated. Data were missing for three VZV-stimulated allo-HSCT recipients.

Altogether, these results suggest an ongoing recovery of VZV-specific immunity in the VZV-responder group. Only 2/15 (13%) had reported HZ-compatible clinical manifestations at 4 and 5 months post-transplant, respectively, while none in the VZV-non-responder group.

***ifn- γ* mRNA Gene Expression in Response to Whole Blood VZV Antigen Stimulation**

To investigate the VZV-specific immune response at the transcriptional level, the relative differential expression (fold change) of *ifn- γ* mRNA at 24 h in VZV-stimulated whole blood was compared to that found in non-stimulated conditions. The VZV responders according to IFN- γ secretion from PBMC ($n = 15$) had a significant fold increase in *ifn- γ* gene expression in whole blood (median [IQR], $12.99 [5.3-79.79]$), whereas the relative expression of *ifn- γ* mRNA was not detected for other allo-HSCT recipients (median [IQR], $0.85 [0.55-1.44]$, $P < .0001$) (Figure 2A). Moreover, *ifn- γ* gene expression in allo-HSCT recipients and HI was significantly correlated with IFN- γ release and percentage of EdU^+ proliferating cells (among CD3^+ cells) (Spearman's correlation coefficients, 0.84 , 95% CI $[0.75-0.9]$ and 0.82 , 95% CI $[0.73-0.89]$, respectively; Figures 2B, C). Overall, these results indicate a consistency between upstream *ifn- γ* gene expression at 24 h in VZV-stimulated whole blood and downstream lymphocyte proliferative and IFN- γ -releasing capacities of PBMC at day 7 in response to VZV antigen. In VZV-naïve controls, *ifn- γ* mRNA was not significantly expressed after VZV stimulation (fold change: $0.66-1.87$). Overall, results of VZV-specific IFA in VZV-naïve pediatric controls confirmed the specificity of these assays.

Post-Transplant T-Cell Immunophenotyping and Correlation With IFN- γ Release

The correlation between VZV-induced IFN- γ release and various T-cell subsets in allo-HSCT recipients was investigated. Although the median absolute CD4^+ T-cell count was lower than normal values (Table 1), the IFN- γ release in response to VZV antigen was positively correlated with absolute counts of naïve ($\text{CD45RA}^+\text{CCR7}^+$) and central memory ($\text{CD45RA}^-\text{CCR7}^+$) CD4^+ T-cells, as well as of naïve ($\text{CD45RA}^+\text{CCR7}^+$) CD8^+ T-cells (Spearman rank-correlation coefficients, $r = 0.35$ (95% CI $[0.08-0.57]$), 0.28 (95% CI $[0.02-0.52]$) and 0.36 (95% CI $[0.10-0.58]$), respectively). When comparing VZV responders and non-responders, median naïve and central memory CD4^+ and naïve CD8^+ T-cell counts were significantly higher in the VZV-responder group ($P = .043$, $P = .01$, $P = .048$, respectively). Of note, no associations were observed between VZV responsiveness and clinical determinants (Table 2).

DISCUSSION

This study provides insights into VZV-specific immune reconstitution after allo-HSCT. We found that 15/57 (26%) of allo-HSCT recipients had recovered a VZV-specific IFN- γ response by 6 months post-transplant, in the absence of any HZ-related clinical event for the majority of them. Interestingly, the measurement of *ifn- γ* gene expression by qPCR at 24 h on a small-volume whole-blood sample could be as effective and less

TABLE 2 | VZV-specific immune responses of allogeneic hematopoietic stem cell transplantation recipients.


	VZV non-responders (n = 42)*	VZV responders (n = 15)	P
7-day VZV-stimulated PBMC, median [IQR]			
IFN- γ release (pg/mL)	0.22 [0.12–0.42]	80.45 [54.3–312.8]	<.0001
EdU ⁺ proliferating cells among CD3 ⁺ cells (%)	0.002 [0.001–0.11]	2.22 [1.18–7.56]	<.0001
24-h VZV-stimulated whole blood[†], median [IQR]			
<i>ifn-γ</i> gene expression (fold change)	0.85 [0.55–1.44]	12.99 [5.30–79.79]	<.0001
Immunophenotyping of lymphocytes and subsets (cells/μL), median [IQR]			
ALC	1,090 [710–2,460]	1,590 [1,000–2,130]	.421
T CD4 ⁺	232.5 [115.5–385.5]	287 [220.5–329]	.319
T CD4 ⁺ N	12.5 [4.75–22.25]	33 [14.5–38]	.043
T CD4 ⁺ CM	40 [17–80]	81 [65.5–114]	.010
T CD4 ⁺ EM	115 [80–208]	157 [116.5–192.5]	.459
T CD4 ⁺ DM	5.5 [1.75–38.75]	3.5 [0–5.75]	.106
T CD8 ⁺	367.5 [218.75–879.25]	364 [237.5–486]	.921
T CD8 ⁺ N	16.5 [9–50.5]	44 [24–70.5]	.048
T CD8 ⁺ CM	10 [2–14.5]	16 [7–30]	.125
T CD8 ⁺ EM	160 [69.5–282.75]	157 [108.5–303]	.490
T CD8 ⁺ DM	225 [60–332]	102 [64.5–140]	.287
NK cells	157 [114–137]	146 [99.5–194]	0.39
Post-transplant VZV IgG titers at inclusion (mIU/mL), median [IQR]	383.1 [141.1–664.2]	1382 [494.4–1577]	.005
Selected clinical variables, n (%)			
AML	20 (48)	9 (60)	.715
ATG	24 (57)	9 (60)	>.999
DLI	5 (12)	3 (20)	.422
Chronic GvHD	5 (12)	3 (20)	.422
IS therapy [‡]	15 (36)	4 (27)	.751

Peripheral blood mononuclear cells (PBMC) (1×10^5 cells) and whole blood from allo-HSCT recipients ($n = 57$) were stimulated by VZV antigen (inactivated supernatants from VZV-infected MRC-5 cells, 20 μ g/ml) or supernatants from VZV-uninfected MRC-5 cells (control condition). IFN- γ release (pg/ml) and the percentage of EdU⁺ proliferating cells (among CD3⁺ cells) were measured after a 7-day VZV stimulation of PBMC by immunoassay (ELLA nanofluidic system) or flow cytometry, respectively. VZV responders were identified based on IFN- γ release strictly above 4.83 pg/ml, corresponding to twice the maximum value observed in the control condition. The *ifn- γ* gene expression level was measured by qPCR in a whole blood sample after 24 h of VZV stimulation. The relative differential expression between VZV-stimulated and non-stimulated conditions is given as the fold change. Immunophenotyping of lymphocyte subsets was performed by flow cytometry on whole blood. Groups were compared using the Mann-Whitney U test or the Fisher's exact test, where appropriate; P-values <.05 were considered statistically significant and are highlighted in bold. *Data were missing for three allo-HSCT recipients. †Data were missing for three allo-HSCT recipients. ‡Immunosuppressive therapy: cyclosporine, tacrolimus, corticosteroids, ruxolitinib. Abbreviations: ALC, absolute lymphocyte count; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CM, central memory; DM, differentiated memory; DLI, donor lymphocyte infusion; EdU, 5-ethynyl-2'-deoxyuridine; EM, effector memory; GvHD, graft-versus-host disease; IFN- γ , interferon- γ ; IgG, immunoglobulin G; IQR, interquartile range; IS, immunosuppressive; N, naïve; VZV, varicella zoster virus.

time-consuming than standard IFA based on the quantification of lymphocyte proliferation and IFN- γ release upon VZV antigen stimulation to identify allo-HSCT recipients that have recovered VZV-specific cell-mediated immunity. In addition, we found that naïve (CD45RA⁺CCR7⁺) T-cell counts and central memory (CD45RA⁻CCR7⁺) CD4⁺ T-cell counts correlated with the reconstitution of the VZV-specific immune repertoire.

Reconstitution of VZV-specific immunity following allo-HSCT is mostly driven by endogenous VZV reexposure, rather than by exogenous reinfection, and can occur with or without clinical manifestations and despite antiviral prophylaxis (20, 21, 30–32). Subclinical VZV reactivations are well described in immunocompromised patients (18–20, 32). In the present study, the majority (13/15, 87%) of VZV responders had not presented any HZ-compatible manifestation, although *in vitro* assays showed detectable VZV-specific immune cell responses. Relative to the entire cohort of allo-HSCT recipients, this proportion of subclinical VZV reactivations (13/60, 22%) is overall consistent with previous studies that reported 26% to 41% of subclinical VZV reactivations among adult bone marrow transplant recipients (20, 33).

Importantly, unresponsiveness to VZV was not associated with the receipt of immunosuppressive treatment, suggesting that the process of immune reconstitution *per se* is individual. IFN- γ release in response to VZV stimulation was correlated with naïve CD4⁺ and CD8⁺ and central memory CD4⁺ T-cell subsets despite low total CD4⁺ T-cell absolute counts. This suggests that thymopoiesis contributes to the reconstitution of cognate cell-mediated immune responses and an antiviral-specific T-cell repertoire (34), rather than survival of host cells or expansion of donor-derived T-cells. Therefore, detection of VZV-specific cell-mediated immunity might be a surrogate marker of the reconstitution of a thymus-dependent, functional T-cell pool after allo-HSCT, although quantitative naïve T-cell assessment did not strongly correlate with functional response. Importantly, the total CD4⁺ T-cell count did not discriminate VZV responders from VZV non-responders: more than half of VZV non-responders had a total CD4⁺ T-cell count above 200/ μ L, a threshold of the immunosuppressive state validated in the context of human immunodeficiency virus infection, but that many clinicians use to guide antimicrobial prophylaxis strategies in other settings of immunodepression.



Furthermore, no hematological or transplant-related characteristic was associated with VZV responsiveness.

Humoral immunity to VZV, measured by IgG antibody titers, is known not to correlate with immune protection, and infusions of blood-derived products, in particular intravenous Ig, can lead to non-interpretable results (8, 20, 22, 35). Consistently, 29/42 (69%) of VZV non-responders had positive VZV IgG values in this study. Different IFA have been proposed to quantify VZV-specific cell-mediated immunity, but there is no validated “gold standard.” VZV-specific T-cell proliferation assays, performed on PBMC or whole blood (5, 20, 22, 36, 37), have several limitations. The first relates to the various origins of IFN- γ production. The correlation between VZV-specific IFN- γ release and T-cell subsets suggests that IFN- γ is mainly secreted by T-cells. To gain the detection sensitivity of VZV-responsive T-cells at the single-cell level, the IFN- γ enzyme-linked immunosorbent spot (ELISPOT) assay has been proposed (9, 31, 32, 38). However, in addition to being labor intensive because of the multiple experimental steps from PBMC preparation to spot detection, enumeration of IFN- γ spot-forming cells proves to be difficult. The second limit relates to the threshold of detection of IFN- γ . Others have reported that IFN- γ release in the supernatant of whole blood incubated with live VZV was not detected before 48 h and peaked at 72 h (22). Consequently, to test the VZV status more rapidly, we formulated the hypothesis that measuring upstream *ifn- γ* gene expression in 24-h-stimulated whole blood would predict the VZV status as effectively as downstream synthesized IFN- γ protein at day 7. qPCR on whole blood is relatively simple to perform, in comparison to various cell-based IFA. To the best of our knowledge, this is the first study assessing the *ifn- γ* gene expression level as a marker of VZV-specific cell-mediated immunity. As PCR techniques are widely used during routine

post-transplant care, the implementation of the VZV-specific *ifn- γ* gene expression assay on whole blood at a lab experienced in the follow-up of allo-HSCT recipients should be relatively easy. The main advantages of PCR assays are their time- and resource-sparing nature, their relative technical ease, and their reproducibility.

Taken together and considering that one quarter of allo-HSCT recipients had detectable VZV-specific cell-mediated immunity by the time of study initiation (6 months post-transplant), measuring the VZV-specific *ifn- γ* gene expression level in whole blood once every trimester after allo-HSCT could help to monitor kinetics of specific immune reconstitution. If assumed as a surrogate marker of VZV-specific immunity, this assay, combined to T-cell immunophenotyping, could ultimately guide antiviral prophylaxis in a personalized manner. This would provide the basis for an interventional, randomized, controlled trial vs. standard of care to test the hypothesis that it is safe to stop antiviral prophylaxis based on a personalized approach using the *ifn- γ* gene expression assay. The primary endpoint would be the absence of HZ reactivation following prophylaxis interruption. An earlier interruption of antiviral prophylaxis could avoid overtreatment and emergence of HSV cross-resistance to acyclovir and limit compliance issues. Other useful applications of the *ifn- γ* gene expression assay could be proposed such as determining VZV-specific immunity status in other patient groups at risk of VZV reactivation (i.e., solid organ transplant recipients, multiple myeloma patients, elderly people) or evaluating cellular response to VZV vaccination.

Beyond antiviral prophylaxis, VZV-related disease can be prevented by vaccination. The inactivated RZV has demonstrated a clinical efficacy of 68.2% to prevent HZ after autologous HSCT and has been recently shown in a prospective cohort study to be safe after allo-HSCT, although immunogenicity data in this setting are

lacking (39, 40). The RZV has been recently recommended to immunocompromised adults, including allo-HSCT recipients, in the USA, but is not currently available in France (41).

This study has limitations. The results of this proof-of-concept study require a validation cohort. We report VZV-specific immunity at a single time point (approximately 6 months post-transplant, due to the design of the VaccHemInf study which aims to study response to the inactivated vaccines which are recommended in this timeframe). The time of 6-month post-transplant corresponds to a pivotal period, when allo-HSCT recipients are usually off immunosuppressive therapy and when immune reconstitution is well underway from a quantitative point of view. We did not assess in this study kinetics of antiviral immune reconstitution. Due to the high seroprevalence of VZV (>95%) among adults in France, the specificity of VZV IFA was confirmed on pediatric samples (42, 43). The choice of VZV antigen (supernatants from VZV-infected MRC-5 cells, inactivated by gamma irradiation), although widely used, can be criticized due to cross-reactivity with other herpesvirus, especially herpes simplex virus-1, as previously reported *in vivo* (44, 45). Peptides based on VZV glycoprotein gE and immediate-early 63 might be more suitable antigens. It would also have been of interest to compare the assay with the intracellular cytokine staining method or the histocompatibility complex-tetramer technology such as previously described for CMV reactivation (46, 47); similarly, for thymopoiesis after allo-HSCT, quantitative assessment of T-cell receptor rearrangement excision circles (TRECs) could have been used as an informative surrogate marker for recipients, as previously described in the setting of viral reactivation (48).

In conclusion, as the management of immunocompromised individuals evolves to increasingly personalized agendas, measurement of VZV-specific cell-mediated immunity by a fast (24-h) *ifn- γ* gene expression assay from a whole-blood sample and immunophenotyping of T-cell subsets could help to monitor antiviral immune repertoire reconstitution after allo-HSCT and ultimately enable a more rationale use of antiviral prophylaxis.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because no patient-level data can be made available, in accordance with data protection laws. Upon reasonable request, aggregate data with different levels of resolution may be possible to provide. Requests to access the datasets should be directed to florence.ader@chu-lyon.fr.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comité de Protection des Personnes Sud-Est V, Grenoble, France (69HCL17_0769). The patients/participants

provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MB contributed to the conception and design of the study and to the acquisition and interpretation of the data and drafted the manuscript. AC and WM contributed to the acquisition and interpretation of the data and drafted the manuscript. CR-S and EF performed the VZV serology assays and contributed to the revision of the paper for important intellectual content. BR provided pediatric control samples and contributed to the revision of the paper for important intellectual content. FVa, VA, HL-W, HG, and KB-P contributed to the interpretation of the data and to the revision of the paper for important intellectual content. FVe contributed to the acquisition of the data of immune functional assays, to the interpretation of the data, and to the revision of the paper for important intellectual content. ST-A contributed to the conception and design of the study, to the acquisition and interpretation of the data, and to the revision of the paper for important intellectual content. FA conceived and designed the study, participated in the analyses and interpretation of the data, and drafted the manuscript. All authors have read and have approved the final version of the manuscript.

FUNDING

This research was funded by an internal grant from the Hospices Civils de Lyon (Appel d'Offre Jeune Chercheur 2018, to AC) and by the Région Auvergne-Rhône-Alpes (Pack Ambition Recherche 2019, to FA).

ACKNOWLEDGMENTS

This work is published on behalf of the **Lyon HEMINF study group**: F. Ader, V. Alcazer, E. Bachy, M. Balsat, F. Barraco, M. Boccard, A. Conrad, S. Ducastelle-Leprêtre, O. Dumitrescu, D. Dupont, V. Escuret, E. Ferrant, T. Ferry, G. Fossard, E. Frobert, H. Ghesquière, M. Heiblig, E. Hodille, L. Karlin, H. Labussière-Wallet, M-V. Larcher, F. Laurent, B. Lina, G. Lina, C. Malcus, G. Monneret, F. Morfin-Sherpa, T. Perpoint, F. Poitevin-Later, M. Rabodonirina, C. Roure-Sobas, V. Safar, P. Sesques, S. Trouillet-Assant, F. Valour, F. Venet, F. Wallet, M. Wallon.

The authors are grateful to the Direction de la Recherche en Santé (DRS) des Hospices Civils de Lyon, as well as to the Région Auvergne-Rhône-Alpes for supporting the VaccHemInf-FIGHT cohort. The authors would like to thank Philip Robinson for the helpful reviewing of the manuscript and Fabien Subtil and Maxime Bodinier for help in statistical analysis. The authors gratefully acknowledge Pr Etienne Javouhey and Dr Solène Rémy for their help to recruit pediatric controls, the staff of the Centre

de Ressources Biologiques Sud and Dr Pierre Sujobert for biobanking of samples from the VaccHemInf-FIGHT cohort, and the Centre de Recherche Clinique Hématologie Sud and the nurses from the hematology department of the Hospices Civils de Lyon for their assistance during the entire study.

REFERENCES

- Han CS, Miller W, Haake R, Weisdorf D. Varicella Zoster Infection After Bone Marrow Transplantation: Incidence, Risk Factors and Complications. *Bone Marrow Transplant* (1994) 13(3):277–83.
- Leung TF, Chik KW, Li CK, Lai H, Shing MMK, Chan PKS, et al. Incidence, Risk Factors and Outcome of Varicella-Zoster Virus Infection in Children After Haematopoietic Stem Cell Transplantation. *Bone Marrow Transplant* (2000) 25(2):167–72. doi: 10.1038/sj.bmt.1702119
- Berman JN, Wang M, Berry W, Neuberg DS, Guinan EC. Herpes Zoster Infection in the Post-Hematopoietic Stem Cell Transplant Pediatric Population may be Preceded by Transaminitis: An Institutional Experience. *Bone Marrow Transplant* (2006) 37(1):73–80. doi: 10.1038/sj.bmt.1705191
- Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, Desjardin J, et al. Varicella Zoster Virus Infections Following Allogeneic Bone Marrow Transplantation: Frequency, Risk Factors, and Clinical Outcome. *Biol Blood Marrow Transplant* (2000) 6(1):44–9. doi: 10.1016/S1083-8791(00)70051-6
- Meyers JD, Flournoy N, Thomas ED. Cell-Mediated Immunity to Varicella-Zoster Virus After Allogeneic Marrow Transplant. *J Infect Dis* (1980) 141(4):479–87. doi: 10.1093/infdis/141.4.479
- Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV and EBV Infections in Patients With Hematological Malignancies and After SCT: Guidelines From the Second European Conference on Infections in Leukemia. *Bone Marrow Transplant* (2009) 43(10):757–70. doi: 10.1038/bmt.2008.386
- Su SH, Martel-Laferrriere V, Labbe AC, Snyderman DR, Kent D, Laverdiere M, et al. High Incidence of Herpes Zoster in Nonmyeloablative Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* (2011) 17(7):1012–7. doi: 10.1016/j.bbmt.2010.10.025
- Arvin AM, Moffat JF, Redman R. Varicella-Zoster Virus: Aspects of Pathogenesis and Host Response to Natural Infection and Varicella Vaccine. *Adv Virus Res* (1996) 46:263–309. doi: 10.1016/S0065-3527(08)60074-3
- Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-Zoster Virus-Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. *J Infect Dis* (2008) 197(6):825–35. doi: 10.1086/528696
- Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in Varicella-Zoster Virus (VZV)-Specific Cell-Mediated Immunity With Increasing Age and Boosting With a High-Dose VZV Vaccine. *J Infect Dis* (2003) 188(9):1336–44. doi: 10.1086/379048
- Laing KJ, Ouwendijk WJD, Koelle DM, Verjans GMGM. Immunobiology of Varicella-Zoster Virus Infection. *J Infect Dis* (2018) 218(suppl_2):S68–74. doi: 10.1093/infdis/jiy403
- Arvin AM. Humoral and Cellular Immunity to Varicella-Zoster Virus: An Overview. *J Infect Dis* (2008) 197 Suppl 2:S58–60. doi: 10.1086/522123
- Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella-Zoster Reactivation After Allogeneic Stem Cell Transplantation Without Routine Prophylaxis—the Incidence Remains High. *Biol Blood Marrow Transplant* (2014) 20(10):1646–9. doi: 10.1016/j.bbmt.2014.06.002
- Geddes M, Storek J. Immune reconstitution following hematopoietic stem-cell transplantation. *Best Pract Res Clin Haematol*. 20(2):329–48. doi: 10.1016/j.beha.2006.09.009
- Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation. *Front Immunol* (2016) 7:507. doi: 10.3389/fimmu.2016.00507
- Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplant Recipients: A Global Perspective. *Biol Blood Marrow Transplant* (2009) 15(10):1143–238. doi: 10.1016/j.bbmt.2009.06.019
- Jamani K, MacDonald J, Lavoie M, Williamson TS, Brown CB, Chaudhry A, et al. Zoster Prophylaxis After Allogeneic Hematopoietic Cell Transplantation Using Acyclovir/Valacyclovir Followed by Vaccination. *Blood Adv* (2016) 1(2):152–9. doi: 10.1182/bloodadvances.2016000836
- Luby JP, Ramirez-Ronda C, Rinner S, Hull A, Vergne-Marini P. A Longitudinal Study of Varicella-Zoster Virus Infections in Renal Transplant Recipients. *J Infect Dis* (1977) 135(4):659–63. doi: 10.1093/infdis/135.4.659
- Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, et al. IE63-Specific T-Cell Responses Associate With Control of Subclinical Varicella Zoster Virus Reactivation in Individuals With Malignancies. *Br J Cancer* (2010) 102(4):727–30. doi: 10.1038/sj.bjc.6605542
- Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B. Clinical and Subclinical Reactivations of Varicella-Zoster Virus in Immunocompromised Patients. *J Infect Dis* (1986) 153(5):840–7. doi: 10.1093/infdis/153.5.840
- Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA. Long-Term Acyclovir for Prevention of Varicella Zoster Virus Disease After Allogeneic Hematopoietic Cell Transplantation—a Randomized Double-Blind Placebo-Controlled Study. *Blood* (2006) 107(5):1800–5. doi: 10.1182/blood-2005-09-3624
- Otani N, Baba K, Okuno T. Interferon-Gamma Release Assay: A Simple Method for Detection of Varicella-Zoster Virus-Specific Cell-Mediated Immunity. *J Immunol Methods* (2009) 351(1–2):71–4. doi: 10.1016/j.jim.2009.09.010
- Terada K, Itoh Y, Fujii A, Kitagawa S, Ogita S, Ouchi K. Varicella-Zoster Virus-Specific, Cell-Mediated Immunity With Interferon-Gamma Release Assay After Vaccination of College Students With No or Intermediate IgG Antibody Response. *J Med Virol* (2015) 87(2):350–6. doi: 10.1002/jmv.24031
- Conrad A, Boccard M, Valour F, Alcazer V, Tovar Sanchez AT, Chidiac C, et al. VaccHemInf Project: Protocol for a Prospective Cohort Study of Efficacy, Safety and Characterisation of Immune Functional Response to Vaccinations in Haematopoietic Stem Cell Transplant Recipients. *BMJ Open* (2019) 9(2):e026093. doi: 10.1136/bmjopen-2018-026093
- Maple P A C, Rathod P, Smit E, Gray J, Brown D, Boxall EH. Comparison of the Performance of the LIAISON VZV-IgG and VIDAS Automated Enzyme Linked Fluorescent Immunoassays With Reference to a VZV-IgG Time-Resolved Fluorescence Immunoassay and Implications of Choice of Cut-Off for LIAISON Assay. *J Clin Virol* (2009) 44(1):9–14. doi: 10.1016/j.jcv.2008.08.012
- Poujol F, Monneret G, Friggeri A, Rimmelé T, Malcus C, Poitevin-Later F, et al. Flow Cytometric Evaluation of Lymphocyte Transformation Test Based on 5-Ethynyl-2'-deoxyuridine Incorporation as a Clinical Alternative to Tritiated Thymidine Uptake Measurement. *J Immunol Methods* (2014) 415:71–9. doi: 10.1016/j.jim.2014.10.006
- Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods* (2001) 25(4):402–8. doi: 10.1006/meth.2001.1262
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. *Blood* (2016) 127(20):2391–405. doi: 10.1182/blood-2016-03-643544
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 Revision to the World Health Organization Classification of Lymphoid Neoplasms. *Blood* (2016) 127(20):2375–90. doi: 10.1182/blood-2016-01-643569
- Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al. Early Reconstitution of Immunity and Decreased Severity of Herpes Zoster in Bone

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.919806/full#supplementary-material>

- Marrow Transplant Recipients Immunized With Inactivated Varicella Vaccine. *J Infect Dis* (1997) 176(3):578–85. doi: 10.1086/514077
31. Distler E, Schnurer E, Wagner E, von Auer C, Plachter B, Wehler D, et al. Recovery of Varicella-Zoster Virus-Specific T Cell Immunity After T Cell-Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation. *Biol Blood Marrow Transplant* (2008) 14(12):1417–24. doi: 10.1016/j.bbmt.2008.09.004
 32. Merindol N, Salem Fourati I, Brito RM, Grenier AJ, Charrier E, Cordeiro P, et al. Reconstitution of Protective Immune Responses Against Cytomegalovirus and Varicella Zoster Virus Does Not Require Disease Development in Pediatric Recipients of Umbilical Cord Blood Transplantation. *J Immunol* (2012) 189(10):5016–28. doi: 10.4049/jimmunol.1201759
 33. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical Varicella-Zoster Virus Viremia, Herpes Zoster, and T Lymphocyte Immunity to Varicella-Zoster Viral Antigens After Bone Marrow Transplantation. *J Infect Dis* (1992) 165(1):119–26. doi: 10.1093/infdis/165.1.119
 34. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, et al. Assessment of Thymic Output in Adults After Haematopoietic Stem-Cell Transplantation and Prediction of T-Cell Reconstitution. *Lancet* (2000) 355(9218):1875–81. doi: 10.1016/S0140-6736(00)02293-5
 35. Webster A, Grint P, Brenner MK, Prentice HG, Griffiths PD. Titration of IgG Antibodies Against Varicella Zoster Virus Before Bone Marrow Transplantation is Not Predictive of Future Zoster. *J Med Virol* (1989) 27(2):117–9. doi: 10.1002/jmv.1890270209
 36. Hayashida K, Ozaki T, Nishimura N, Gotoh K, Funahashi K, Nakane K, et al. Evaluation of Varicella Zoster Virus-Specific Cell-Mediated Immunity by Using an Interferon- γ Enzyme-Linked Immunosorbent Assay. *J Immunol Methods* (2015) 426:50–5. doi: 10.1016/j.jim.2015.07.011
 37. Yang P, Chen Z, Zhang J, Li W, Zhu C, Qiu P, et al. Evaluation of Varicella-Zoster Virus-Specific Cell-Mediated Immunity by Interferon- γ Enzyme-Linked Immunosorbent Assay in Adults \geq 50 Years of Age Administered a Herpes Zoster Vaccine. *J Med Virol* (2019) 91(5):829–35. doi: 10.1002/jmv.25391
 38. Salem Fourati I, Grenier AJ, Jolette É, Merindol N, Ovetchkine P, Soudeyns H. Development of an IFN- γ ELISpot Assay to Assess Varicella-Zoster Virus-Specific Cell-Mediated Immunity Following Umbilical Cord Blood Transplantation. *J Vis Exp* (2014) (89):51643. doi: 10.3791/51643
 39. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. *JAMA* (2019) 322(2):123–33. doi: 10.1001/jama.2019.9053
 40. Baumrin E, Izaguirre NE, Bausk B, Feeley MM, Bay CP, Yang Q, et al. Safety and Reactogenicity of the Recombinant Zoster Vaccine After Allogeneic Hematopoietic Cell Transplantation. *Blood Adv* (2021) 5(6):1585–93. doi: 10.1182/bloodadvances.2020003749
 41. Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged \geq 19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. *MMWR Morb Mortal Wkly Rep* (2022) 71(3):80–4. doi: 10.15585/mmwr.mm7103a2
 42. Khoshnood B, Debruyne M, Lançon F, Emery C, Fagnani F, Durand I, et al. Seroprevalence of Varicella in the French Population. *Pediatr Infect Dis J* (2006) 25(1):41–4. doi: 10.1097/01.inf.0000195636.43584.bb
 43. Saadatian-Elahi M, Mekki Y, Del Signore C, Lina B, Derrough T, Caulin E, et al. Seroprevalence of Varicella Antibodies Among Pregnant Women in Lyon-France. *Eur J Epidemiol* (2007) 22(6):405–9. doi: 10.1007/s10654-007-9136-z
 44. Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, et al. Extensive CD4 and CD8 T Cell Cross-Reactivity Between Alphaherpesviruses. *J Immunol* (2016) 196(5):2205–18. doi: 10.4049/jimmunol.1502366
 45. Chiu C, McCausland M, Sidney J, Duh FM, Roupheal N, Mehta A, et al. Broadly Reactive Human CD8 T Cells That Recognize an Epitope Conserved Between VZV, HSV and EBV. *PLoS Pathog* (2014) 10(3):e1004008. doi: 10.1371/journal.ppat.1004008
 46. Gratama JW, van Esser JW, Lamers CH, Tournay C, Löwenberg B, Bolhuis RL, et al. Tetramer-Based Quantification of Cytomegalovirus (CMV)-Specific CD8+ T Lymphocytes in T-Cell-Depleted Stem Cell Grafts and After Transplantation may Identify Patients at Risk for Progressive CMV Infection. *Blood* (2001) 98(5):1358–64. doi: 10.1182/blood.V98.5.1358
 47. Raeeszadeh M, Pachnio A, Begum J, Craddock C, Moss P, Chen FE. Characterization of CMV-Specific CD4+ T-Cell Reconstitution Following Stem Cell Transplantation Through the Use of HLA Class II-Peptide Tetramers Identifies Patients at High Risk of Recurrent CMV Reactivation. *Haematologica* (2015) 100(8):e318–22. doi: 10.3324/haematol.2015.123687
 48. Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, et al. Clearance of CMV Viremia and Survival After Double Umbilical Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis. *Blood* (2010) 115(20):4111–9. doi: 10.1182/blood-2009-09-244145

Conflict of Interest: WM has a PhD grant CIFRE 2019 (conventions industrielles de formation par la recherche, Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation, Paris, France) half-funded by Lyon University and half-funded by bioMérieux SA. KB-P is an employee of bioMérieux SA, an *in vitro* diagnostic company.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Boccard, Conrad, Mouton, Valour, Roure-Sobas, Frobert, Rohmer, Alcazer, Labussière-Wallet, Ghesquière, Venet, Brengel-Pesce, Trouillet-Assant and Ader. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.